

**XAF1 Antibody (C-Terminus)**  
**Rabbit Polyclonal Antibody**  
**Catalog # ALS11507****Specification**

---

**XAF1 Antibody (C-Terminus) - Product Information**

Application	IF, IHC
Primary Accession	<a href="#">Q6GPH4</a>
Reactivity	Human, Mouse
Host	Rabbit
Clonality	Polyclonal
Calculated MW	35kDa KDa

**XAF1 Antibody (C-Terminus) - Additional Information****Gene ID** 54739**Other Names**

XIAP-associated factor 1, BIRC4-binding protein, XAF1, BIRC4BP, XIAPAF1

**Target/Specificity**

synthetic peptide corresponding to amino acids at the C-terminus of human XAF-1

**Reconstitution & Storage**

Short term 4°C, long term aliquot and store at -20°C, avoid freeze thaw cycles. Store undiluted.

**Precautions**

XAF1 Antibody (C-Terminus) is for research use only and not for use in diagnostic or therapeutic procedures.

**XAF1 Antibody (C-Terminus) - Protein Information****Name** XAF1**Synonyms** BIRC4BP, XIAPAF1**Function**

Seems to function as a negative regulator of members of the IAP (inhibitor of apoptosis protein) family. Inhibits anti-caspase activity of BIRC4. Induces cleavage and inactivation of BIRC4 independent of caspase activation. Mediates TNF-alpha-induced apoptosis and is involved in apoptosis in trophoblast cells. May inhibit BIRC4 indirectly by activating the mitochondrial apoptosis pathway. After translocation to mitochondria, promotes translocation of BAX to mitochondria and cytochrome c release from mitochondria. Seems to promote the redistribution of BIRC4 from the cytoplasm to the nucleus, probably independent of BIRC4 inactivation which seems to occur in the cytoplasm. The BIRC4-XAF1 complex mediates down-regulation of BIRC5/survivin; the process requires the E3 ligase activity of BIRC4. Seems to be involved in cellular sensitivity to the proapoptotic actions of TRAIL. May be a tumor suppressor by mediating apoptosis resistance of cancer cells.

**Cellular Location**

Cytoplasm. Nucleus. Mitochondrion. Note=Found in the cytoplasm and nucleus of placental syncytiotrophoblasts Translocates to mitochondria upon TNF-alpha treatment [Isoform 5]: Nucleus.


**Tissue Location**

Widely expressed. Expression is frequently down- regulated in cancer cell lines. Isoform 5 is widely expressed Expressed in placenta (at protein level).


**XAF1 Antibody (C-Terminus) - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

**XAF1 Antibody (C-Terminus) - Images**

Immunofluorescence of XAF-1 in Human Spleen cells with XAF-1 antibody at 10 ug/ml.



Anti-XAF1 antibody IHC of human prostate.

**XAF1 Antibody (C-Terminus) - Background**

Seems to function as a negative regulator of members of the IAP (inhibitor of apoptosis protein) family. Inhibits anti- caspase activity of BIRC4. Induces cleavage and inactivation of BIRC4 independent of caspase activation. Mediates TNF-alpha- induced apoptosis and is involved in apoptosis in trophoblast cells. May inhibit BIRC4 indirectly by activating the mitochondrial apoptosis pathway. After translocation to mitochondria, promotes translocation of BAX to mitochondria and cytochrome c release from mitochondria. Seems to promote the redistribution of BIRC4 from the cytoplasm to the nucleus, probably independent of BIRC4 inactivation which seems to occur in the cytoplasm. The BIRC4-XAF1 complex mediates down-regulation of BIRC5/survivin; the process requires the E3 ligase activity of BIRC4. Seems to be involved in cellular sensitivity to the proapoptotic actions of TRAIL. May be a tumor suppressor by mediating apoptosis resistance of cancer cells.

**XAF1 Antibody (C-Terminus) - References**

Liston P.,et al.Nat. Cell Biol. 3:128-133(2001).  
Chung S.K.,et al.Gastroenterology 132:2459-2477(2007).  
Ota T.,et al.Nat. Genet. 36:40-45(2004).  
Mural R.J.,et al.Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.  
Bechtel S.,et al.BMC Genomics 8:399-399(2007).